title: Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant.
abstract: Some trials in premature infants with respiratory distress syndrome have shown an increased incidence of patent ductus arteriosus after exogenous surfactant therapy. The effect of prophylactic ethamsylate on patent ductus arteriosus after intratracheal administration of a single dose of porcine surfactant preparation (Curosurf, 2.5 ml/kg) was studied in a group of 20 preterm infants with severe respiratory distress syndrome. Gestational age of the patients was 29.2 +/- 2.5 weeks (mean +/- SD), and birth weight was 1158 +/- 319 gm. Ethamsylate (12.5 mg/kg) was given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days. Hemodynamically significant patent ductus arteriosus occurred more frequently in the untreated group (8 of 10) than in the ethamsylate group (2 of 10) (p < 0.02). No acute adverse effects were attributed to the therapy. This preliminary experience suggests that ethamsylate, an inhibitor of prostaglandin biosynthesis, could be useful in reducing the incidence of patent ductus arteriosus in very low birth weight infants treated with exogenous surfactant.
authors.affiliation: Department of Obstetrics and Gynecology, University of Berne, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Amato
authors.forename: P
authors.initials: P
authors.lastname: Hüppi
authors.forename: D
authors.initials: D
authors.lastname: Markus
mesh_terms: D001688:Biological Products; D004374:Ductus Arteriosus, Patent / Q000139:chemically induced / Q000517:prevention & control*; D004979:Ethamsylate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D010743:Phospholipids; D011446:Prospective Studies; D011659:Pulmonary Gas Exchange; D011663:Pulmonary Surfactants / Q000009:adverse effects / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; D004979:Ethamsylate; C068291:poractant alfa